TransCelerate other news

TransCelerate launched its Clinical Trial Comparator Network to establish reliable and rapid sourcing of comparator drug products for use in clinical trials. The organization said a master service agreement was executed in July by several undisclosed member companies to offer secure and rapid supply of comparator drug products. Currently, TransCelerate said unless there is a specific agreement is in place between biopharmaceutical companies, companies frequently are unable to secure comparators and co-therapies directly from each other, and therefore must purchase on the open market.

The network is one of TransCelerate's five clinical trial initiatives. The other initiatives are development of a shared user interface for investigator site portals; mutual recognition of study site qualification and training; development of clinical data standards; and development of risk-based site monitoring approaches and standards. Earlier this year, TransCelerate published a position paper outlining a methodology for risk-based trial site monitoring (see BioCentury, June 10). ...